Blueprint Medicines (BPMC) Stock Forecast & Price Target

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

$85.18

-2.07 (-2.37%)

(As of 04/15/2024 ET)

Blueprint Medicines Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 14 Analyst Ratings

Analysts' Consensus Price Target

$85.43
0.29% Upside

High Forecast	$115.00
Average Forecast	$85.43
Low Forecast	$43.00

Type	Current Forecast 4/17/23 to 4/16/24	1 Month Ago 3/18/23 to 3/17/24	3 Months Ago 1/17/23 to 1/17/24	1 Year Ago 4/17/22 to 4/17/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	6 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$85.43	$85.43	$81.00	$72.68
Predicted Upside	0.29% Upside	14.43% Upside	19.81% Upside	43.41% Upside

Get Blueprint Medicines Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

BPMC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BPMC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Blueprint Medicines Stock vs. The Competition

Type	Blueprint Medicines	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.68	2.48
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	0.29% Upside	882.04% Upside	11.23% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/10/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$114.00	+28.12%
2/26/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$97.00	+8.39%
2/16/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$54.00 ➝ $65.00	-27.78%
2/13/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$58.00 ➝ $70.00	-9.72%
2/5/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$97.00	+26.53%
1/9/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$95.00 ➝ $97.00	+13.70%
Get the Latest News and Ratings for BPMC and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.
12/22/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy ➝ Strong-Buy	$85.00 ➝ $100.00	+16.37%
12/19/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$86.00 ➝ $115.00	+31.26%
12/11/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$85.00	+14.90%
10/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$59.00 ➝ $63.00	+14.09%
10/27/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$85.00	+53.93%
8/3/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$93.00 ➝ $83.00	+52.85%
6/5/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
6/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$48.00 ➝ $43.00	-26.14%
5/23/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$78.00 ➝ $82.00	+45.78%
5/5/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:13 AM ET.

BPMC Price Target - Frequently Asked Questions

What is Blueprint Medicines's consensus rating and price target?: According to the issued ratings of 14 analysts in the last year, the consensus rating for Blueprint Medicines stock is Moderate Buy based on the current 3 sell ratings, 2 hold ratings, 8 buy ratings and 1 strong buy rating for BPMC. The average twelve-month price prediction for Blueprint Medicines is $85.43 with a high price target of $115.00 and a low price target of $43.00. Learn more on BPMC's analyst rating history.
Do Wall Street analysts like Blueprint Medicines more than its competitors?: Analysts like Blueprint Medicines less than other Medical companies. The consensus rating score for Blueprint Medicines is 2.50 while the average consensus rating score for medical companies is 2.68. Learn more on how BPMC compares to other companies.
Does Blueprint Medicines's stock price have much upside?: According to analysts, Blueprint Medicines's stock has a predicted upside of 14.57% based on their 12-month stock forecasts.

What analysts cover Blueprint Medicines?: Blueprint Medicines has been rated by Barclays, Citigroup, JMP Securities, Needham & Company LLC, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:BPMC) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Blueprint Medicines (BPMC) Stock Forecast & Price Target

Blueprint Medicines Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

BPMC Analyst Ratings By Month

BPMC Price Targets by Month

Blueprint Medicines Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

BPMC Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info